Lineage to Present at 3 rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the 3 rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3 rd Annual H.C. Wainwright BioConnect Investor Conference takes place on Tuesday, May 20, 2025, at the Nasdaq stock exchange headquarters in New York, NY.
Investors interested in scheduling an in-person meeting with the Lineage management team should contact their H.C. Wainwright representative or email meetings@hcwco.com. A replay of Lineage's fireside chat will be available on the Events and Presentations section of Lineage's website, following the conclusion of the conference.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, 'off-the-shelf,' cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen ®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance™ (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Avangrid Invests In The Next Generation With Its 2025 Summer Internship Program
ORANGE, Conn.--(BUSINESS WIRE)--Avangrid, Inc., a leading energy company and member of the Iberdrola Group, this week launched its 2025 Summer Internship Program. This year, the company welcomes 71 interns from over 50 universities across the United States and abroad, including participants from Spain and Mexico. Interns will be based at Avangrid offices located in New York, Maine, Connecticut, Massachusetts, and Oregon, and will join 20 different departments including IT, Communications, and Networks. 'At Avangrid, attracting and nurturing emerging talent is one of our key priorities,' said Avangrid CEO Pedro Azagra. 'Our internship program is designed to help students strengthen their skills and gain real-world experience before entering the workforce. Through workshops, speaker sessions, and peer networking events like Cohort Connects, we aim to equip them with the tools they need for a successful, differentiated and fulfilling career.' Kicking off on June 2, the Internship Experience will demonstrate Avangrid's dedication to career growth by teaching skills such as analytical thinking, project coordination, and professional resilience. New interns will participate in sessions focused on practical, job-ready skills, while returning interns will deepen their learning through speaker sessions with senior leaders who bring those skills to life. 'Offering this unique internship experience to students across the nation is essential,' said Ignacio Estella, Senior Vice President for Talent & Performance, Innovation and Equal Opportunity. 'Our goal is to 'electrify' talent with solid career opportunities in the transformational energy sector with a local and global leader, and to showcase the differentiated career paths that Avangrid can offer to the next generation of professionals.' The Internship Experience follows a 70/20/10 learning model designed to maximize growth: 70% of learning happens through hands-on, business-critical projects; 20% through relationship-building with mentors, peers, and leaders; and 10% through formal training, such as workshops and speaker sessions. Interns conclude the program by presenting a five-minute pitch showcasing their achievements—an opportunity that often leads to full-time roles or entry into Avangrid's Rotational Graduate Program. 'Being part of this program has already been an incredible opportunity,' said June Monasterios, a rising senior at Gannon University and an intern in the Internal Audit team. 'Even in just the first week, I've felt both welcomed and inspired. I'm beginning to understand not only the energy industry, but also how to grow as a professional. It's exciting to be part of a company that truly values sustainability, innovation, and its people.' About Avangrid: Avangrid, Inc. is a leading energy company in the United States working to meet the growing demand for energy for homes and businesses across the nation through service, innovation, and continued investments by expanding grid infrastructure and energy generation projects. Avangrid has offices in Connecticut, New York, Massachusetts, Maine and Oregon, including operations in 23 states with approximately $47 billion in assets, and has two primary lines of business: networks and power. Through its networks business, Avangrid owns and operates eight electric and natural gas utilities, serving more than 3.3 million customers in New York and New England and in 2024. Through its power generation business, Avangrid owns and operates more than 75 energy generation facilities across the United States producing 10.5 GW of power for over 3.1 million customers. Avangrid employs approximately 8,000 people and has been recognized by JUST Capital as one of the JUST 100 companies – a ranking of America's best corporate citizens in 2025 for the fifth consecutive year. The company was named among the World's Most Ethical Companies in 2025 for the seventh consecutive year by the Ethisphere Institute. Avangrid is a member of the group of companies controlled by Iberdrola, S.A. For more information, visit
Yahoo
25 minutes ago
- Yahoo
The $1.3 Billion Health-Tech IPO Everyone Missed--Until It Soared 21% on Day One
Omada Health (NASDAQ:OMDA) opened its first day of trading with a bangjumping 21% to $23 after pricing its IPO at $19. That move gives the digital chronic-care startup a market cap of roughly $1.3 billion. The $150 million raise was more than just well receivedinvestor demand came in more than 15x oversubscribed, with most allocations going to a concentrated group of institutional buyers. It's another sign that appetite for health-tech IPOs is heating up again. U.S. listings have raised nearly $25 billion year-to-date, and early-stage healthcare names are up an average of 18% since listing. Founded in 2011, Omada offers virtual care between doctor visitsfocused on diabetes, obesity, hypertension, and joint pain. What sets it apart? It's not chasing the GLP-1 gold rush. Instead, Omada supports people already on those drugs, helping them manage side effects, nutrition, and post-treatment maintenance. About 50,000 of its 679,000 members are on GLP-1s. CEO Sean Duffy told Bloomberg that while AI powers much of the back-end, real human interaction is what drives results. Our members tell us they want a personand I have yet to see anyone that feels accountable to ChatGPT, he said. Revenue for Q1 2025 came in just under $55 millionup from $35.1 million a year agowhile net losses narrowed by more than half to $9.4 million. That improving financial picture, combined with a clear niche in chronic care, could be what's drawing top-tier investors. Revelation Partners, Andreessen Horowitz, Fidelity, and USVP are all among the largest shareholders. The IPO was led by Morgan Stanley, Goldman Sachs, and JPMorgan. OMDA now trades on the Nasdaq Global Marketand it's one more sign that digital health might be staging a real comeback. This article first appeared on GuruFocus.
Yahoo
30 minutes ago
- Yahoo
Omada Health Soars 42% in Nasdaq Debut After $150 Million IPO
Omada Health (OMDA, Financials) surged 42% in its Nasdaq debut Friday after the virtual chronic care company priced its initial public offering at $19 per share, raising $150 million and securing a valuation just above $1 billion. The stock opened at $23 and climbed quickly past $27. Warning! GuruFocus has detected 8 Warning Sign with X. Founded in 2012, Omada offers virtual programs for chronic conditions including prediabetes, diabetes, and hypertension. The IPO, which sold 7.9 million shares, is part of a recent resurgence in health and tech listings, following last month's debut of Hinge Health and Thursday's surge in Circle Internet shares. In its prospectus, Omada reported Q1 revenue jumped 57% year over year to $55 million, while full-year 2024 revenue rose 38% to $169.8 million. The company narrowed its net loss in the most recent quarter to $9.4 million from $19 million a year earlier. Major outside shareholders include U.S. Venture Partners, Andreessen Horowitz, and Fidelity's FMR LLC, each holding a 9% to 10% stake. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
